Compare Fox Corp Class A (FOXA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Summit Therapeutics Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.36B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 0.91% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Summit Therapeutics Inc for 16 Days on average.
| FOXA | SMMT | |
|---|---|---|
Market Cap | $25.36B | $13.71B |
Volume | 2,566,954 | 6,173,057 |
Sector | Media | Health |
52-Week High | $76.11 | $26.38 |
52-Week Low | $48.79 | $12.43 |
Typical Hold Time | 34 Days | 16 Days |
Enterprise Value | $28.72B | $13.04B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.41, down 0.46% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 16.3% revenue growth to $16.30B in 2025 and three consecutive quarterly earnings beats. The pending $22B Roku acquisition, currently under DOJ review, represents a major strategic development. Analyst consensus is bullish with a $72.00 price target and no sell ratings among 48 analysts.
The outlook is positive given strong earnings momentum, reasonable valuation (P/E 16.55), and potential upside from the Roku deal. Key risks include regulatory hurdles for the acquisition and a projected decline in 2026 net income. The stock offers a compelling risk-reward profile for investors seeking exposure to media consolidation.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
